血塞通注射液对糖尿病视网膜病变临床前期血栓素B_2及6-酮-前列腺素F_(1α)的干预作用  

Xuesaitong Injection Intervenes on TXB_2 and 6-keto-PGF_(1α) of Diabetic Retinopathy in Per-clinic

作　　者：刘莹[1] 

机构地区：[1]甘肃中医学院临床医学院,甘肃兰州730020

出　　处：《中国中医药信息杂志》2005年第1期23-23,56,共2页Chinese Journal of Information on Traditional Chinese Medicine

摘　　要：目的 观察血塞通注射液对糖尿病视网膜病变临床前期的干预作用及疗效评价。方法 将符合诊断标准的 63 例糖尿病性视网膜病变临床前期患者随机分为观察组(44 例)和对照组(41 例)。观察组给予血塞通注射液,对照组不予任何处理。观察治疗前后的血栓素 B2(TXB2)及 6-酮-前列腺素 F1α(6-keto-PGF1α)的含量变化、评价疗效。结果 与对照组比较,血塞通注射液能显著下调 TXB2含量(P <0.01),上调 6-keto-PGF1α含量(P <0.01),ARR=100.0%、RR=0、RRR=100.0%、NNT=1(例)。结论 血塞通注射液能显著干预和阻止糖尿病性视网膜病变;疗效评价显示治疗效果好,临床价值大。Objective To observe Xuesaitong Injection intervenes diabetic retinopathy in per-clinic and evaluates the effects. Methods There were data of 63 patients accord with diagnose criterion of diabetic retinopathy in per-clinic had been divided into observed group (44 cases) and control group (41 cases) randomly. Xuesaitong Injection was applied in observed group, and nothing in control group. We investigated the changes of TXB2 and 6-keto-PGF1α before and after treatment, and evaluated the curative effects of Xuesaitong Injection. Results Xuesaitong Injection can ascend 6-keto-PGF1 (P <0.01) and descend TXB2 (P <0.01). ARR=100%, RR=0, RRR=100%, NNT=1. α Conclusion Xuesaitong Injection can dramatically intervene and prevent diabetic retinopathy. The evaluation shows the effects are good and the clinical value is remarkable.

关 键 词：血塞通注射液 糖尿病视网膜病变 

分 类 号：R587.26[医药卫生—内分泌]